
Plexus (PLXS) Stock Forecast & Price Target
Plexus (PLXS) Analyst Ratings
Bulls say
Plexus Corp has demonstrated resilience in its Healthcare/Life Sciences segment, which generated $424 million in revenue for FQ4, reflecting a year-over-year increase of 2% and a quarter-over-quarter rise of 1%, with full-year revenues rising to $1.629 billion. Expectations for future growth remain strong, with the segment projected to achieve high-single-digit to low-double-digit growth in FQ1, driven by multiple program ramps and recovering customer demand. Furthermore, contributions from the Aerospace and Defense segment are anticipated to bolster overall revenue growth, aligning with the company's goal of 9-12% growth for FY26, supported by ongoing success in commercial air and defense initiatives.
Bears say
Plexus Corp's gross margin has declined to 9.9%, down from 10.1% in the previous quarter, indicating potential pressures on profitability. The company anticipates a decrease in Industrial revenues in the upcoming quarter due to seasonality and moderating demand, which, alongside a stagnation in Aerospace & Defense revenues, raises concerns about overall revenue stability. Additionally, company-specific risks—including manufacturing disruptions, demand shortfalls in key verticals, and competitive challenges—pose significant threats to Plexus's market position and operational effectiveness.
This aggregate rating is based on analysts' research of Plexus and is not a guaranteed prediction by Public.com or investment advice.
Plexus (PLXS) Analyst Forecast & Price Prediction
Start investing in Plexus (PLXS)
Order type
Buy in
Order amount
Est. shares
0 shares